Compare Mesoblast Limited (MESO) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Tripadvisor Inc Common Stock — how do they compare? Mesoblast Limited trades at $16.36 (market cap $2.17B), while Tripadvisor Inc Common Stock trades at $13.88 (market cap $1.68B). The key difference: Mesoblast Limited is the larger of the two by market cap. Which is the better fit depends on your goals.
| MESO | TRIP | |
|---|---|---|
Market Cap | $2.17B | $1.68B |
Sector | Technology | Consumer Cyclical |
52-Week High | $20.96 | $19.14 |
52-Week Low | $12.88 | $9.24 |
Enterprise Value | $2.17B | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Tripadvisor (TRIP) trades at $14.38, down 1.37% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported Q1 2026 earnings miss but maintains strong gross margins of 91.95%. Recent $700 million sale of TheFork to American Express provides capital flexibility while focusing on core travel experiences business. Revenue growth remains modest at $1.89B in 2025 with net margin improving to 2.11%.
Outlook remains cautious with analyst consensus at Hold (60.72%) and $13.87 price target below current levels. The stock faces headwinds from competitive pressures and macroeconomic uncertainty, though the strategic divestiture and travel recovery trends offer potential upside. Key risks include execution challenges and market volatility amid mixed earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
